Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.50 – $9.83
64% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $864.0K | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $664.0K | $168.0K | $251.0K | $424.0K | $330.0K |
| Gross profit | $0 | $0 | $0 | $200.0K | −$168.0K | −$251.0K | −$424.0K | −$330.0K |
| Gross margin | — | — | — | 23.1% | — | — | — | — |
| R&D | $0 | $0 | $321.6K | $3.3M | $17.6M | $26.1M | $32.4M | $54.9M |
| Operating income | −$189.9K | −$80.5K | −$2.0M | −$31.0M | −$63.8M | −$51.5M | −$78.8M | −$143.1M |
| EBITDA | −$220.8K | −$101.0K | $9.6K | −$32.2M | −$63.7M | −$51.3M | −$78.6M | −$142.7M |
| Net income | −$220.8K | −$101.0K | −$1.9M | −$32.2M | −$71.4M | −$40.0M | −$78.1M | −$113.1M |
| Net margin | — | — | — | -3729.2% | — | — | — | — |
| EPS (diluted) | -0.69 | -0.01 | -0.04 | -3221645.62 | -0.43 | -0.22 | -9.41 | -0.61 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $13M | $-3.38 | $-3.38–$-3.38 | 3 |
| 2028 | $22M | $-3.41 | $-4.18–$-2.43 | 3 |
| 2029 | $0 | $-0.23 | $-0.23–$-0.23 | 1 |
| 2030 | $0 | $3.29 | $3.29–$3.29 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CYBN.
No tracked institution reports a position in CYBN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-09-19 | 1-for-38reverse |
No one on the platform has traded CYBN yet.
| $107M |
| — |
| MOLNMolecular Partners AG | $3.80 | -3.31% | $143M | — |
| NKTXNkarta, Inc. | $2.83 | +1.80% | $202M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.